Investment analysts at Truist Financial started coverage on shares of Harmony Biosciences (NASDAQ:HRMY - Get Free Report) in a report released on Monday, MarketBeat Ratings reports. The firm set a "buy" rating and a $48.00 price target on the stock. Truist Financial's target price indicates a potential upside of 30.25% from the company's previous close.
A number of other brokerages have also recently commented on HRMY. UBS Group dropped their price target on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Monday, April 28th. Mizuho boosted their price target on Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a research report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $55.00 price target (up from $54.00) on shares of Harmony Biosciences in a research report on Thursday, July 10th. Oppenheimer began coverage on shares of Harmony Biosciences in a report on Monday, June 2nd. They issued an "outperform" rating and a $61.00 price objective for the company. Finally, Needham & Company LLC restated a "buy" rating and issued a $49.00 price objective on shares of Harmony Biosciences in a report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $51.00.
View Our Latest Stock Analysis on Harmony Biosciences
Harmony Biosciences Stock Down 1.0%
Shares of HRMY traded down $0.37 during mid-day trading on Monday, reaching $36.85. The company had a trading volume of 120,510 shares, compared to its average volume of 665,836. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.63 and a current ratio of 3.67. The firm has a 50-day moving average price of $33.96 and a 200 day moving average price of $33.95. Harmony Biosciences has a 52 week low of $26.47 and a 52 week high of $41.61. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of 14.07, a price-to-earnings-growth ratio of 0.50 and a beta of 0.83.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.19. Harmony Biosciences had a return on equity of 24.32% and a net margin of 20.53%. The firm had revenue of $184.73 million for the quarter, compared to analysts' expectations of $184.26 million. During the same period in the previous year, the firm posted $0.67 EPS. The business's revenue for the quarter was up 19.5% compared to the same quarter last year. On average, sell-side analysts forecast that Harmony Biosciences will post 2.43 EPS for the current year.
Institutional Investors Weigh In On Harmony Biosciences
A number of hedge funds have recently added to or reduced their stakes in HRMY. Financial Management Professionals Inc. purchased a new stake in shares of Harmony Biosciences in the 1st quarter worth $29,000. Brooklyn Investment Group increased its stake in shares of Harmony Biosciences by 1,031.9% in the 1st quarter. Brooklyn Investment Group now owns 1,064 shares of the company's stock worth $35,000 after purchasing an additional 970 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Harmony Biosciences in the 4th quarter worth $41,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Harmony Biosciences in the 1st quarter worth $57,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Harmony Biosciences by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,218 shares of the company's stock worth $70,000 after purchasing an additional 299 shares in the last quarter. 86.23% of the stock is currently owned by hedge funds and other institutional investors.
Harmony Biosciences Company Profile
(
Get Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Recommended Stories

Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.